help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pacak, K.
Right arrow Articles by Goldstein, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pacak, K.
Right arrow Articles by Goldstein, D. S.
Endocrine Reviews 25 (4): 568-580
Copyright © 2004 by The Endocrine Society

Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography

Karel Pacak, Graeme Eisenhofer and David S. Goldstein

Pediatric and Reproductive Endocrinology Branch (K.P.), National Institute of Child Health and Human Development; and Clinical Neurocardiology Section (D.S.G., G.E.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892

Correspondence: Address all correspondence and requests for reprints to: Karel Pacak, M.D., Ph.D., D.Sc., Unit on Clinical Neuroendocrinology, Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 9D42, 10 Center Drive MSC-1583, Bethesda, Maryland 20892-1583. E-mail: karel{at}mail.nih.gov

This article provides an update on functional imaging approaches for diagnostic localization of endocrine tumors, with emphasis on positron emission tomography (PET). [18F]Fluorodeoxyglucose PET scanning is now a widely accepted imaging approach in clinical oncology. Benefits include improved patient outcome facilitated by staging and monitoring of disease and better treatment planning. [18F]Fluorodeoxyglucose PET is also useful in some endocrine tumors, particularly in recurrent or metastatic thyroid cancer where the degree of accumulation of the radionuclide has prognostic value. However, this imaging approach does not take full advantage of the unique characteristics of endocrine tumors. Endocrine tumor cells take up hormone precursors, express receptors and transporters, and synthesize, store, and release hormones. These characteristics offer highly specific targets for PET. Radiopharmaceuticals developed for such approaches include 6-[18F]fluorodopamine, and [11C]hydroxyephedrine for localization of pheochromocytomas, [11C]5-hydroxytryptophan and [11C]L-dihydroxyphenylalanine for carcinoid tumors, and [11C]metomidate for adrenocortical tumors. These functional imaging approaches are not meant to supplant conventional imaging modalities but should be used conjointly to better identify specific characteristics of endocrine tumors. This represents a relatively new and evolving approach to imaging that promises to answer specific questions about the behavior and growth of endocrine tumors, their malignant potential, and responsiveness to different treatment modalities.




This article has been cited by other articles:


Home page
JNMHome page
I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, A. Ling, I. Lazurova, K. T. Adams, S. Perera, and K. Pacak
Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma
J. Nucl. Med., October 1, 2008; 49(10): 1613 - 1619.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
T. Zelinka, H. J L M Timmers, A. Kozupa, C. C Chen, J. A Carrasquillo, J. C Reynolds, A. Ling, G. Eisenhofer, I. Lazurova, K. T Adams, et al.
Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations
Endocr. Relat. Cancer, March 1, 2008; 15(1): 311 - 323.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J R Meinardi, B H R Wolffenbuttel, and R P F Dullaart
Cyclic Cushing's syndrome: a clinical challenge
Eur. J. Endocrinol., September 1, 2007; 157(3): 245 - 254.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Alesci, S. M. Perera, E. W. Lai, C. Kukura, M. Abu-Asab, M. Tsokos, J. C. Morris, and K. Pacak
Adenoviral Gene Transfer in Bovine Adrenomedullary and Murine Pheochromocytoma Cells: Potential Clinical and Therapeutic Relevance
Endocrinology, August 1, 2007; 148(8): 3900 - 3907.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. M. Zuetenhorst and B. G. Taal
Metastatic Carcinoid Tumors: A Clinical Review
Oncologist, February 1, 2005; 10(2): 123 - 131.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society